The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities ...
The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...
The last time I spoke about Absci Corporation (ABSI), it was in a Seeking Alpha article entitled "Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile." The hope here ...
VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with ...
HC Wainwright reiterated their buy rating on shares of Absci (NASDAQ:ABSI – Free Report) in a research report report published on Wednesday,Benzinga reports. They currently have a $7.00 price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results